There were 1,706 press releases posted in the last 24 hours and 402,225 in the last 365 days.

Generex Takes TheStreet.com To Court Over 'Misleading Statements'

April 13, 2010 (FinancialWire) — Generex Biotechnology Corp. (NASDAQ: GNBT) recently commenced legal proceedings against TheStreet.com, Inc. and Adam Feuerstein in the Supreme Court of the State of New York seeking $250,000,000 in damages for business defamation, product disparagement, and injurious falsehood.

The claims arise out of articles authored by Feuerstein and published on TheStreet.com website on March 19 and March 26, 2010, which Generex contends contained defamatory and misleading statements about it, its management, and its flagship product, Oral-lyn.

TheStreet.com has reported that the Indian government revoked its approval of Oral-lyn in March 2009.

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [ltgnltgn]